(RTTNews) - Incyte (INCY) and Syndax Pharmaceuticals (SNDX) announced that the U.S. Food and Drug Administration has approved Niktimvo (axatilimab-csfr) in 9 mg and 22 mg vial sizes. The Companies ...

While the 2025 Majestor gets revisions to its exterior and interior design, it still comes with the same powertrain options as its outgoing version Exterior highlights include a huge grille ...

The M9 positions MG in the premium electric MPV segment and will be offered exclusively through the brand's 'Select' dealerships MG to retail the premium M9 MPV via its new ‘Select’ dealerships.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The FDA has approved Incyte’s and Syndax’s Niktimvo (axatilimab-csfr) in 9 mg and 22 mg vial sizes for the treatment of chronic graft-versus-host disease (GVHD) in adults and pediatric patients ...

2-Year U.S. Treasury Note Continuous Contract $102.719-0.016-0.02% 5-Year U.S. Treasury Note Continuous Contract $106.055-0.109-0.10% 10-Year U.S. Treasury Note Continuous Contract $108.344-0.203 ...

As one of the world’s biggest contributors to climate change, pharma is morally obliged to adapt its processes and operations – and doing so will open up new opportunities for growth.

Niktimvo will be available for healthcare providers to order through a network of specialty distributors in both 9 mg vial and 22 mg vial sizes to facilitate patient dosing. Incyte and Syndax are ...

After hours: January 17 at 6:56:04 PM EST Loading Chart for VTLE ...

IPC Indice de Precios Y Cotizaciones 49,940.89-7.26-0.01% ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...